L’INESSS recommande le remboursement public pour ORLADEYO® (bérotralstat) de BioCryst pour la prévention des crises chez les patients atteints d’angio-oedème héréditaire au Québec
18 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., 18 sept. 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq : BCRX) a annoncé aujourd’hui que l’Institut national d’excellence en santé et services sociaux...
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec
18 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 sept. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
BioCryst to Present at Upcoming Investor Conferences
23 août 2023 16h01 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2023 16h01 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
03 août 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP...
BioCryst to Report Second Quarter 2023 Financial Results on August 3
20 juil. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results...
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
19 juil. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals...
BioCryst to Participate in the 2023 US HAEA National Summit
17 juil. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its participation at the 2023 US Hereditary Angioedema Association...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...